Clinical Trial Update: A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study [Phase 4]

View source ↗

Summary

The CINAMMON Phase 4 trial evaluating cerebrospinal fluid inflammatory markers after adding maraviroc to darunavir/ritonavir in HIV treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Norvir (ritonavir)
• PREZISTA (darunavir)
• Selzentry (Maraviroc)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV | Phase 4 | Status: COMPLETED